CASIA OpenIR
Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma
Song, Jiangdian1,2; Tian, Jie3; Zhang, Lina2; Qu, Xiujuan2; Qian, Wei4,5; Zheng, Bin5,6; Zhang, Lina7; Zhao, Jia2; Niu, Meng8; Zhou, Mu9; Cui, Lei1; Liu, Yunpeng2; Zhao, Mingfang2
Source PublicationEUROPEAN RADIOLOGY
ISSN0938-7994
2019-05-01
Volume29Issue:5Pages:2388-2398
Corresponding AuthorLiu, Yunpeng(ypliu@cmu.edu.cn) ; Zhao, Mingfang(mfzhao@cmu.edu.cn)
AbstractObjectivesTo establish a pre-therapy prognostic index model (PIM) of the first-line chemotherapy aiming to achieve accurate prediction of time to progression (TTP) and overall survival among the patients diagnosed with locally advanced (stage III) or distant metastasis (stage IV) lung squamous cell carcinoma (LSCC).MethodsNinety-six LSCC patients treated with first-line chemotherapy were retrospectively enrolled to build the model. Fourteen epidermal growth factor receptor (EGFR)-mutant LSCC patients treated with first-line EGFR-tyrosine kinase inhibitor (TKI) therapy were enrolled for validation dataset. From CT images, 56,000 phenotype features were initially computed. PIM was constructed by integrating a CT phenotype signature selected by the least absolute shrinkage and selection operator and the significant blood-based biomarkers selected by multivariate Cox regression. PIM was then compared with other four prognostic models constructed by the CT phenotype signature, clinical factors, post-therapy tumor response, and Glasgow Prognostic Score.ResultsThe signature includes eight optimal features extracted from co-occurrence, run length, and Gabor features. By using PIM, chemotherapy efficacy of patients categorized in the low-risk, intermediate-risk, and high-risk progression subgroups (median TTP=7.2months, 3.4months, and 1.8months, respectively) was significantly different (p<0.0001, log-rank test). Chemotherapy efficacy of the low-risk progression subgroup was comparable with EGFR-TKI therapy (p=0.835, log-rank test). Prognostic prediction of chemotherapy efficacy by PIM was significantly higher than other models (p<0.05, z test).ConclusionThe study demonstrated that the PIM yielded significantly higher performance to identify individual stage III-IV LSCC patients who can potentially benefit most from first-line chemotherapy, and predict the risk of failure from chemotherapy for individual patients.Key Points center dot TTP and OS of first-line chemotherapy in individual stage III-IV LSCC patients could be predicted by pre-therapy blood-based biomarkers and image-based signatures.center dot Risk status of pre-therapy indicators affected the efficacy of first-line chemotherapy in stage III-IV LSCC patients.center dot Those stage III-IV LSCC patients who were able to achieve similar efficacy to EGFR-TKI therapy through chemotherapy were identified.
KeywordBiomarkers Tumor Carcinoma Squamous cell Prognosis
DOI10.1007/s00330-018-5912-2
WOS KeywordOPEN-LABEL ; HEPATOCELLULAR-CARCINOMA ; IMAGING PHENOTYPES ; CANCER ; PREDICTION ; SURVIVAL ; PHASE-3 ; MULTICENTER ; DOCETAXEL ; RISK
Indexed BySCI
Language英语
Funding ProjectNational Key R&D Program of China[2016YFC1303800] ; China Postdoctoral Science Foundation[2018 M630310]
Funding OrganizationNational Key R&D Program of China ; China Postdoctoral Science Foundation
WOS Research AreaRadiology, Nuclear Medicine & Medical Imaging
WOS SubjectRadiology, Nuclear Medicine & Medical Imaging
WOS IDWOS:000463157200025
PublisherSPRINGER
Citation statistics
Document Type期刊论文
Identifierhttp://ir.ia.ac.cn/handle/173211/24917
Collection中国科学院自动化研究所
Corresponding AuthorLiu, Yunpeng; Zhao, Mingfang
Affiliation1.China Med Univ, Sch Med Informat, Shenyang, Liaoning, Peoples R China
2.China Med Univ, Dept Med Oncol, Hosp 1, Shenyang 110001, Liaoning, Peoples R China
3.Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, Beijing, Peoples R China
4.Univ Texas El Paso, Coll Engn, El Paso, TX 79968 USA
5.Northeastern Univ, Sino Dutch Biomed Engn Sch, Shenyang, Liaoning, Peoples R China
6.Univ Oklahoma, Med & Biol Informat Engn, Norman, OK 73019 USA
7.China Med Univ, Hosp 1, Dept Radiol, Shenyang, Liaoning, Peoples R China
8.China Med Univ, Hosp 1, Dept Intervent Therapy, Shenyang, Liaoning, Peoples R China
9.Stanford Univ, Dept Radiol, AIMI Ctr, San Francisco, CA USA
Recommended Citation
GB/T 7714
Song, Jiangdian,Tian, Jie,Zhang, Lina,et al. Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma[J]. EUROPEAN RADIOLOGY,2019,29(5):2388-2398.
APA Song, Jiangdian.,Tian, Jie.,Zhang, Lina.,Qu, Xiujuan.,Qian, Wei.,...&Zhao, Mingfang.(2019).Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma.EUROPEAN RADIOLOGY,29(5),2388-2398.
MLA Song, Jiangdian,et al."Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma".EUROPEAN RADIOLOGY 29.5(2019):2388-2398.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Song, Jiangdian]'s Articles
[Tian, Jie]'s Articles
[Zhang, Lina]'s Articles
Baidu academic
Similar articles in Baidu academic
[Song, Jiangdian]'s Articles
[Tian, Jie]'s Articles
[Zhang, Lina]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Song, Jiangdian]'s Articles
[Tian, Jie]'s Articles
[Zhang, Lina]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.